Comparative Pharmacology
Head-to-head clinical analysis: HEXALEN versus OXALIPLATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXALEN versus OXALIPLATIN.
HEXALEN vs OXALIPLATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing cells.
Oxaliplatin is a platinum-based alkylating agent that forms inter- and intrastrand DNA crosslinks, inhibiting DNA replication and transcription, leading to cell death.
260 mg/m2/day orally in 4 divided doses for 14 or 21 days of a 28-day cycle.
85 mg/m² intravenously over 2 hours every 2 weeks in combination with 5-fluorouracil and leucovorin (FOLFOX regimen).
None Documented
None Documented
Terminal elimination half-life is 12-13 hours; prolonged to 24 hours in renal impairment.
Clinical Note
moderateOxaliplatin + Digoxin
"Oxaliplatin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateOxaliplatin + Digitoxin
"Oxaliplatin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateOxaliplatin + Deslanoside
"Oxaliplatin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateOxaliplatin + Acetyldigitoxin
"Oxaliplatin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 40-50 hours for ultrafilterable platinum (active species) and 240-500 hours for total platinum (bound to plasma proteins and erythrocytes). The prolonged half-life reflects slow release from tissue binding.
Primarily renal and hepatic metabolism; 60-70% excreted in urine as unchanged drug and metabolites; 15-20% eliminated in feces via biliary secretion.
Renal excretion accounts for approximately 50% of the administered platinum, with the remainder eliminated via biliary/fecal routes. Platinum accumulates in erythrocytes and is slowly cleared.
Category C
Category D/X
Alkylating Agent
Alkylating Agent